PT-262 - 99%, high purity , CAS No.86811-36-1

  • ≥99%
Item Number
P650473
Grouped product items
SKUSizeAvailabilityPrice Qty
P650473-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$120.90
P650473-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$190.90
P650473-25mg
25mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$380.90
P650473-50mg
50mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$620.90
P650473-100mg
100mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$980.90

Basic Description

Specifications & Purity≥99%
Biochemical and Physiological MechanismsPT-262 is a potent ROCK inhibitor with an IC 50 value of around 5 μM. PT-262 induces the loss of mitochondrial membrane potential and elevates the caspase-3 activation and apoptosis . PT-262 inhibits the ERK and CDC2 phosphorylation via a p53-independent
Storage TempStore at 2-8°C,Protected from light,Desiccated
Shipped InWet ice
Product Description

PT-262 is a potent ROCK inhibitor with an IC 50 value of around 5 μM. PT-262 induces the loss of mitochondrial membrane potential and elevates the caspase-3 activation and apoptosis . PT-262 inhibits the ERK and CDC2 phosphorylation via a p53-independent pathway. PT-262 blocks cytoskeleton function and cell migration. PT-262 has anti-cancer activity

In Vitro

PT-262 (5-40 μM; 24 h) induces cytotoxicity and proliferation inhibition in human lung cancer cells. PT-262 (2-20 μM; 4-24 h) induces caspase-3 activation, mitochondrial dysfunction and apoptosis in lung cancer cells. PT-262 (10-20 μM; 24 h) induces the accumulation of G2/M phases in both the p53-wild type and p53- lung cancer cells, and inhibits the phosphorylation of CDC2 proteins. PT-262 (0-10 μM; 24 h) represses ERK phosphorylation in lung cancer cells. PT-262 (2 μM; 24 h) induces the cytoskeleton alteration and cell elongation in lung carcinoma A549 cells. PT-262 (2-10 μM; 6 h) significantly blocks the cell migration in a concentration-dependent manner. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: A549 cells Concentration: 5-40 μM Incubation Time: 24 h Result: Reduced the cell viability via a concentration-dependent manner in A549 cells. The IC 50 value toward human normal lung fibroblast was >20 μM. Apoptosis AnalysisCell Line: A549 cells Concentration: 2-20 μM Incubation Time: 4-24 h Result: The apoptotic cells were increased after treatment at 10 μM for 8-24 h. The active forms of caspase-3 (12 and 17 kD) were induced following treatment with 2-20 μM for 24 h. Cell Cycle AnalysisCell Line: A549 and H1299 cells Concentration: 10-20 μM Incubation Time: 24 h Result: Significantly decreased the G1 fractions while increased the G2/M fractions in both A549 and H1299 cells with 10 μM for 24 h. Decreased the protein levels of cyclin B1 and phospho-CDC2 at Thr14, Tyr15, and Thr161 via a concentration-dependent manner in A549 cells. Western Blot AnalysisCell Line: A549 cells Concentration: 0-10 μM Incubation Time: 24 h Result: Significantly inhibited the phosphorylation of ERK.

Form:Solid

IC50& Target:ROCK|5 μM (IC|50|)|ERK|CDK2

AI Insight

Names and Identifiers

Canonical SMILES C1CCN(CC1)C2=C(C(=O)C3=C(C2=O)C=CC=N3)Cl
Isomeric SMILES C1CCN(CC1)C2=C(C(=O)C3=C(C2=O)C=CC=N3)Cl
PubChem CID 12424014
Molecular Weight 276.72

Certificates(CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Related Documents

Reviews

Customer Reviews

Solution Calculators